Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Q3 2025 value amounting to $4.7 million.

  • Rhythm Pharmaceuticals' Interest Expenses fell 953.83% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 1182.77%. This contributed to the annual value of $20.6 million for FY2024, which is 4830.84% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Interest Expenses is $4.7 million, which was down 953.83% from $5.8 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Interest Expenses' 5-year high stood at $5.8 million during Q2 2025, with a 5-year trough of $46000.0 in Q2 2022.
  • In the last 4 years, Rhythm Pharmaceuticals' Interest Expenses had a median value of $4.6 million in 2023 and averaged $3.9 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Interest Expenses soared by 708043.48% in 2023 and then crashed by 953.83% in 2025.
  • Rhythm Pharmaceuticals' Interest Expenses (Quarter) stood at $3.0 million in 2022, then surged by 51.11% to $4.6 million in 2023, then increased by 19.71% to $5.4 million in 2024, then decreased by 12.94% to $4.7 million in 2025.
  • Its Interest Expenses stands at $4.7 million for Q3 2025, versus $5.8 million for Q2 2025 and $5.4 million for Q1 2025.